by Raynovich Rod | Apr 15, 2014 | Biopharmaceuticals, Life Science ETF's and Mutual Funds
Update at Close 4/15….. Late Day Reversal To Green The NASDAQ Composite began a rally at 1P EDT and never stopped , moving up 62 points to close at 4034. Biotech ETFs followed step by step to end up in the green after a severe daily decline. The IBB ($217.6) ended up...
by Raynovich Rod | Apr 11, 2014 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Top Ten Reasons For Biotech Correction NASDAQ at 4022,IBB at 221 A Sentiment Driven Market We have been writing about the bull market in biotech stocks since its inception in March 2009 when quality companies were advancing their pipelines and new products in...
by Raynovich Rod | Apr 9, 2014 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update 4/10 Abrupt Sell-Off –Failure to Confirm Bottom NASDAQ down 71 pts 1.7% All of yesterdays’ gains wiped out and we are back to January levels. Raise cash levels to 30% on life science portfolios. Many high fliers and core holdings are selling off...
by Raynovich Rod | Apr 8, 2014 | 2025 Rayno Biopharmaceuticals Portfolio
NASDAQ Up 0.37% to 4133 Green screen alert with large cap biotechs. Time to cover hedges. Alexion (ALXN) up 2.23% Biogen (BIIB) Up 2.4% Celgene (CELG) up 3.61% Clovis Oncology (CLVS) up 2.85% Gilead (GILD) up 1.35% IBB up 1.96% Regeneron (REGN) up 3.99% Key Trends To...
by Raynovich Rod | Apr 3, 2014 | Biopharmaceuticals, Life Science ETF's and Mutual Funds
Update 4/4/14 Breach of Technicals-A Tad Below Early February Support Glut of Biotech IPOs Causing Indigestion? Momentum Days Are So Over NASDAQ Down 1.34% The volatile and speculative SPDR S&P Biotech XBI hit $136 in early trading down 2.28%.After a brief rally...
by Raynovich Rod | Apr 1, 2014 | 2025 Rayno Biopharmaceuticals Portfolio
Rayno Biopharmaceutical Portfolio 3/31/14 Most of our biotech picks did well in a tough quarter that went through a severe correction in early February and again in late March. Many small and mid-cap momentum stocks were crushed but indices (FBT,IBB) overall held the...
by Raynovich Rod | Mar 31, 2014 | Biopharmaceuticals
Large Cap Biopharmaceutical Growth Stocks With the MoMo days over the next earnings cycle (Q1,Q2 2014) should give us better clarity on winners for 2014.On the last day of March all of these large caps rallied after a severe one week correction from 3/21-28. Watch...
by Raynovich Rod | Mar 26, 2014 | Biopharmaceuticals
12:15p EDT 3/26 With NASDAQ down 0.64% and the IBB down 0.6% here are some green stocks: Rayno Life Science Portfolio: AMGN up 0.53%, CPHD up 1.43%, GILD up 0.57%, and REGN up 0.84%. Other Notables on our watch list: CLVS up 4%, CONX up 11%, FMI up 2.7%, KERX up...
by Raynovich Rod | Mar 26, 2014 | Biopharmaceuticals
(See Full Article in Seeking Alpha 3/26) Biopharmaceutical Downdraft 15% From February Highs (IBB$239) Large Cap Biopharmaceutical Stocks Are Core Holdings: ABBV, AMGN, GILD The biotech frenzy of MoMo investing is over so it is time to invest longer term with quality...
by Raynovich Rod | Mar 21, 2014 | Biopharmaceuticals, Life Science ETF's and Mutual Funds
Biotech Stocks Will Need To Rebuild Confidence With Momentum Gone Damage on Friday 3/21 was considerable but most indices/ETFs are above 2014 Feb 6 low: FBIOX ($206.4) Up 13.6% YTD, FEB 5 low $196.24 IBB ($246) Up 8.35% YTD, FEB 6 low $237. PBE ($43.33) Up 16.94%...
